Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Bacterial Infection: early-phase trial registry

2 of 9 indexed Bacterial Infection trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

9 US clinical trials · 2 currently recruiting · #1,916 of 28,707 conditions by registered trial count

Bacterial Infection: 9 US clinical trials tracked, 2 recruiting.

Bacterial Infection is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 3 of these trials.

Enrollment posture brief

Registry condition bacterial-infection

OPEN 2 | RECR 22% | LATE 2 | EARLY 5 | RANK #1916 | SPON 3

Nearest open-share peer: Acne (22% recruiting · 27 trials)

Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%Acute Otitis Media22.2%Bacterial Infection (this)22%Acute Heart Failure11.1%
Open-enrollment share among volume-matched conditions near Bacterial Infection

Bacterial Infection lists 2 open slots (22% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Bacterial Infection on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Bacterial Infection is recruiting below its size-band peers.

    2 of 9 indexed trials (22.2%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Bacterial Infection research.

    National Institute of Allergy and Infectious Diseases (NIAID) accounts for 3 of 9 trials (33.3%). 7 distinct sponsors appear on at least one study for this condition label.

  3. Typical Bacterial Infection enrolment sits around 54 participants.

    Median target enrolment is 54 among the 9 trials that report a genuine target (sentinel values excluded). 5 of those (55.6%) plan for fewer than 100 participants.

  4. Bacterial Infection research is mostly interventional.

    8 interventional and 1 observational studies make up this index (88.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 23Phase 42

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 4 150 participants

Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI)

National Institute of Allergy and Infectious Diseases (NIAID)

NCT06709521

RECRUITING Phase 4 54 participants

Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea

Bausch Health Americas

NCT07285785

COMPLETED Phase 2 215 participants

Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections

Cellceutix Corporation

NCT02052388

COMPLETED Phase 2 150 participants

Efficacy and Safety of Ceftaroline Versus Linezolid in Subjects With Complicated Skin and Skin Structure Infections

Forest Laboratories

NCT00633152

COMPLETED 136 participants

Incidence of Antibiotic Resistant E.Coli in Patients Undergoing Repeat Prostate Biopsy

University of California, Irvine

NCT00915213

COMPLETED Phase 1 48 participants

A Trial to Evaluate the Pharmacokinetics and Safety of AVYCAZ(R) in Combination With Aztreonam

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03978091

COMPLETED NA 45 participants

Larval Debridement Therapy Versus Sharp Debridement to Remove Biofilm

North Florida Foundation for Research and Education

NCT02294175

COMPLETED Phase 2 29 participants

Study to Assess Safety and Clinical Activity of Local MBN-101 in Treatment of Infected Bone Sites

Microbion Corporation

NCT02436876

COMPLETED Phase 1 16 participants

Safety of Intravenous Apramycin in Adults

National Institute of Allergy and Infectious Diseases (NIAID)

NCT05590728

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 3
Phase 4 2

Named interventions

Most-linked intervention names on Bacterial Infection records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

MBN-101 Drug
1 trials
Ceftazidime-Avibactam Drug
1 trials
AZACTAM Drug
1 trials
linezolid Drug
1 trials
ceftaroline Drug
1 trials
Apramycin (EBL-1003) Drug
1 trials
Bedside Sharp Debridement Procedure
1 trials
Larval Debridement Therapy Device
1 trials

US sites by state

Facility locations filed on Bacterial Infection trials. A trial with sites in several states counts in each.

California 5 trials
Ohio 3 trials
Florida 3 trials
Virginia 2 trials
Texas 2 trials
Pennsylvania 2 trials
North Carolina 2 trials
Tennessee 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Bacterial Infection page

9 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Bacterial Infection condition card totals 9 registered trials; most-linked intervention MBN-101; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.